Skip to main content
editorial
. 2015 Sep 14;21(34):9833–9837. doi: 10.3748/wjg.v21.i34.9833

Table 1.

Summary of the Sendai Consensus Guidelines and Fukuoka Consensus Guidelines

Guideline Criteria
SCG
MD-IPMN MPD ≥ 10 mm
SCG+ve BD-IPMN Size > 3 cm
Size ≤ 3 cm with symptoms/mural nodules/MPD dilation (> 6 mm)/ positive cytology
FCG
High risk features Proximal lesion with obstructive jaundice
Enhancing nodules
Dilated main duct (≥ 10 mm)
Worrisome risk features Size ≥ 3 cm
Pancreatitis
Non-enhancing nodules
Thickened, enhancing walls
Dilated duct (5 to < 10 mm)
Change in duct caliber with distal atrophy
Lymphadenopathy

FCG: Fukuoka; SCG: Sendai Consensus Guidelines; MPD: Main pancreatic duct; MD-IPMN: Main-duct intraductal papillary mucinous neoplasm; BD-IPMN: Branch-duct intraductal papillary mucinous neoplasm.